WJ Gradishar

881 total citations
48 papers, 718 citations indexed

About

WJ Gradishar is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, WJ Gradishar has authored 48 papers receiving a total of 718 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in WJ Gradishar's work include Cancer Treatment and Pharmacology (28 papers), Advanced Breast Cancer Therapies (15 papers) and HER2/EGFR in Cancer Research (11 papers). WJ Gradishar is often cited by papers focused on Cancer Treatment and Pharmacology (28 papers), Advanced Breast Cancer Therapies (15 papers) and HER2/EGFR in Cancer Research (11 papers). WJ Gradishar collaborates with scholars based in United States, Brazil and Portugal. WJ Gradishar's co-authors include V. Craig Jordan, Everett E. Vokes, Ruth O’Regan, Allen S. Lichter, Beryl McCormick, G. W. Sledge, R. Theriault, KD Miller, Robert W. Carlson and Lori J. Goldstein and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

WJ Gradishar

48 papers receiving 682 citations

Peers

Countries citing papers authored by WJ Gradishar

Since Specialization

Citations

This map shows the geographic impact of WJ Gradishar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by WJ Gradishar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites WJ Gradishar more than expected).

Fields of papers citing papers by WJ Gradishar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by WJ Gradishar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by WJ Gradishar. The network helps show where WJ Gradishar may publish in the future.

Co-authorship network of co-authors of WJ Gradishar

This figure shows the co-authorship network connecting the top 25 collaborators of WJ Gradishar. A scholar is included among the top collaborators of WJ Gradishar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with WJ Gradishar. WJ Gradishar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	415P Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer 2024 ·Annals of Oncology ·(unknown), (unknown), Elisabetta Molteni, (unknown), (unknown), (unknown), (unknown), Caterina Gianni, (unknown), Kyle C. Strickland, (unknown), (unknown), Paolo D’Amico, Andrew A. Davis, John K. Donahue, Zhihong Liu, WJ Gradishar, (unknown), (unknown), (unknown)	1
2	Abstract P3-01-19: HER2-positive circulating tumor cells (CTCs) in advanced breast cancer (BC): A feature independent of BC subtype 2019 ·Cancer Research ·(unknown), Lorenzo Gerratana, (unknown), (unknown), (unknown), Giovanna Rossi, Chenhui Wang, (unknown), Haifeng Yang, Lisa Flaum, Maysa Abu‐Khalaf, Amir Behdad, (unknown), Leonidas C. Platanias, WJ Gradishar, Massimo Cristofanilli	2
3	Abstract PD4-05: Patterns of genomic alterations in ER-positive advanced breast cancer patients treated with CDK4/6 inhibitors 2018 ·Cancer Research ·(unknown), (unknown), Timothy Taxter, (unknown), Amir Behdad, WJ Gradishar, (unknown), (unknown)	3
4	BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (BC) 2016 ·Annals of Oncology ·Melanie Royce, (unknown), Mustafa Özgüroğlu, Thomas Bachelot, Sérgio Jobim Azevedo, (unknown), Roberto Hegg, Marc Debled, WJ Gradishar, C. Manlius, Antonia Ridolfi, Jaw‐Town Lin, François Ringeisen, Fátima Cardoso	11
5	ERK-regulated αB-crystallin induction by matrix detachment inhibits anoikis and promotes lung metastasis in vivo 2015 ·Oncogene ·Dmitry Malin, Elena Strekalova, Vladimír Petrovič, (unknown), Bhawna Sharma, Andrey Ugolkov, WJ Gradishar, Vincent L. Cryns	29
6	Elevated incidence of fractures in women with invasive breast cancer 2015 ·Osteoporosis International ·Beatrice J. Edwards, WJ Gradishar, Marilyn E. Smith, Jennifer A. Pacheco, Jaimee Holbrook, June M. McKoy, Beatrice Nardone, (unknown), (unknown), Alfred Rademaker, Irene Helenowski, Andrew D. Bunta, Paula H. Stern, Steven T. Rosen, Dennis P. West, Theresa A. Guise	17
7	Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab 2013 ·Annals of Oncology ·WJ Gradishar	44
8	Multivariate analysis (MVA) of progression-free survival (PFS) in two phase IIb, multinational, double-blind, randomized, placebo (PL)-controlled trials evaluating sorafenib (SOR) plus standard chemotherapy in patients (pts) with HER2-negative locally advanced or metastatic breast cancer (BC). 2010 ·Journal of Clinical Oncology ·WJ Gradishar, (unknown), Virginia Kaklamani, (unknown), (unknown), J. G. M. Segalla, (unknown), Hélio Pinczowski, (unknown), José Baselga	4
9	A regional subgroup analysis of a multinational, double-blind, randomized, placebo-controlled, phase IIb study evaluating sorafenib (SOR) with paclitaxel (PAC) in patients (pts) with advanced breast cancer (BC). 2010 ·Journal of Clinical Oncology ·(unknown), Virginia Kaklamani, (unknown), (unknown), Shailesh Bondarde, Minish Jain, Lee S. Schwartzberg, WJ Gradishar	1
10	Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer 2008 ·European Journal of Cancer Supplements ·Matti Aapro, S. Tjulandin, Paul Bhar, WJ Gradishar	1
11	Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC) 2008 ·European Journal of Cancer Supplements ·WJ Gradishar, D. Krasnojon, Sergey Cheporov, (unknown), G. Manikhas, Alicia Clawson, Paul Bhar	6
12	HER2 and SPARC status in tumors may play an important role in the relative effectiveness of nanoparticle albumin-bound (nab(r)) paclitaxel versus polysorbate-based docetaxel 2008 ·European Journal of Cancer Supplements ·Neil Desai, (unknown), Lindsay Hwang, Runze Wu, (unknown), Patrick Soon‐Shiong, WJ Gradishar	1
13	Efficacy of Nab-paclitaxel in patients with poor prognostic factors or with anthracycline-resistant metastatic breast cancer (MBC) 2008 ·Journal of Clinical Oncology ·Svetislava J. Vukelja, Joyce O’Shaughnessy, D. Krasnojon, Sergey Cheporov, (unknown), G. Manikhas, Paul Bhar, WJ Gradishar	1
14	A phase I trial of pegylated liposomal anthracycline and lapatinib (L) combination in the treatment of metastatic breast cancer (MBC): First evaluation of an anthracycline and lapatinib combination in the treatment of MBC 2007 ·Journal of Clinical Oncology ·(unknown), Steven T. Rosen, Jamie H. Von Roenn, Alfred Rademaker, S. D. Rubin, (unknown), (unknown), WJ Gradishar	6
15	Dose-dense (DD) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD Treatment: Update by CALGB on Breast Cancer Intergroup Trial C9741 with ECOG, SWOG, & NCCTG 2005 ·Journal of Clinical Oncology ·(unknown), D. A. Berry, C. Cirrincione, R. B. Livingston, WJ Gradishar, (unknown), Hyman B. Muss, Larry Norton, EP Winer, C. Hudis	11
16	The cost effectiveness of tamoxifen in the prevention of breast cancer. 1999 ·PubMed ·(unknown), Roger Becker, WJ Gradishar, (unknown), (unknown)	19
17	Clinical potential of new antiestrogens. 1997 ·Journal of Clinical Oncology ·WJ Gradishar, V. Craig Jordan	106
18	Clinical and cytogenetic responses to granulocyte-macrophage colony- stimulating factor in therapy-related myelodysplasia 1992 ·Blood ·WJ Gradishar, MM Le Beau, (unknown), JW Vardiman, Richard A. Larson	21
19	Vascular events in patients receiving high‐dose infusional 5‐fluorouracil‐based chemotherapy: The University of Chicago experience 1991 ·Medical and Pediatric Oncology ·WJ Gradishar, Everett E. Vokes, Richard L. Schilsky, Ralph R. Weichselbaum, W. R. Panje	21
20	Review: 5-Fluorouracil cardiotoxicity: A critical review 1990 ·Annals of Oncology ·WJ Gradishar, Everett E. Vokes	95

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact